These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 30509935)

  • 1. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
    Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
    Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
    Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
    Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
    Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
    McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
    Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
    Islam K; Sime FB; Wallis SC; Bauer MJ; Forde BM; Harris P; Shirin T; Habib ZH; Flora MS; Roberts JA
    J Antimicrob Chemother; 2022 Aug; 77(9):2448-2455. PubMed ID: 35724128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
    Namikawa H; Yamada K; Fujimoto H; Oinuma KI; Tochino Y; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
    Intern Med; 2017; 56(14):1807-1815. PubMed ID: 28717075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
    Maillard A; Delory T; Bernier J; Villa A; Chaibi K; Escaut L; Contejean A; Bercot B; Robert J; El Alaoui F; Tankovic J; Poupet H; Cuzon G; Lafaurie M; Surgers L; Joseph A; Paccoud O; Molina JM; Bleibtreu A;
    Int J Antimicrob Agents; 2023 Jul; 62(1):106809. PubMed ID: 37028731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
    Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.
    Lu B; Wong M; Ha D; Bounthavong M; Banaei N; Deresinski S; Diep C
    J Antimicrob Chemother; 2023 Apr; 78(4):1009-1014. PubMed ID: 36879495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
    Retamar P; López-Cerero L; Muniain MA; Pascual Á; Rodríguez-Baño J;
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3402-4. PubMed ID: 23612190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae.
    Zohar I; Schwartz O; Yossepowitch O; David SSB; Maor Y
    J Antimicrob Chemother; 2020 Feb; 75(2):458-465. PubMed ID: 31691817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of susceptibility and response to therapy with piperacillin-tazobactam in patients with infections caused by Escherichia coli with extended-spectrum β-lactamase (ESBL) CTX-M].
    Álvarez J; Rojas Á; Carvajal C; Revello J; Meza P; Guggiana P; García P; Labarca J
    Rev Chilena Infectol; 2018 Aug; 35(4):343-350. PubMed ID: 30534919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
    Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
    Rodríguez-Baño J; Navarro MD; Retamar P; Picón E; Pascual Á;
    Clin Infect Dis; 2012 Jan; 54(2):167-74. PubMed ID: 22057701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.